Mizuho Sets $100 Target on Tempus AI, Shares Jump Over 4%
Tempus AI shares surged over 4% after Mizuho initiated coverage with an Outperform rating and set a $100 price target. The company also unveiled its HRD-RNA algorithm for detecting homologous recombination deficiency in tumors, with clinical rollout planned later this year, as earnings are slated for Feb. 24.
1. Mizuho Initiates Coverage
Mizuho's analyst Bradley Bowers opened coverage on Tempus AI with an Outperform rating and established a $100 price target, driving a 4.22% share price gain in the latest session.
2. HRD-RNA Algorithm Launch
Tempus AI introduced its HRD-RNA algorithm for detecting homologous recombination deficiency in tumors, leveraging transcriptome analysis to guide platinum-based chemotherapy and PARP inhibitor treatments, with clinical availability expected later this year.
3. Earnings Preview
Tempus AI will report Q4 earnings on Feb. 24, with consensus estimates forecasting a 14-cent per share loss, improving from an 18-cent loss, and projected revenue of $364.45 million.
4. ETF Holding Impact
Tempus AI represents 8.63% of ARKG's portfolio, meaning its post-coverage share movement and upcoming earnings could materially influence ARKG's net asset value and sector exposure.